Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$1.25 and traded as high as C$2.48. Helix BioPharma shares last traded at C$2.13, with a volume of 6,776 shares traded.
Helix BioPharma Trading Down 14.1%
The business’s fifty day simple moving average is C$1.86 and its 200 day simple moving average is C$1.25. The stock has a market cap of C$162.69 million, a P/E ratio of -2.07 and a beta of 0.12.
Helix BioPharma Company Profile
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Featured Articles
- Five stocks we like better than Helix BioPharma
- What does consumer price index measure?
- This AI Chip Giant Could Be the Market’s Next Big Winner
- Breakout Stocks: What They Are and How to Identify Them
- Broadcom Inks OpenAI Deal: Why It’s A Huge Win for AVGO Stock
- What is a penny stock? A comprehensive guide
- Institutions Are Fueling CrowdStrike’s Next Leg Higher
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
